Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 4;79(11):2916-2922.
doi: 10.1093/jac/dkae306.

Increased mortality in hospital- compared to community-onset carbapenem-resistant enterobacterales infections

Affiliations

Increased mortality in hospital- compared to community-onset carbapenem-resistant enterobacterales infections

Angelique E Boutzoukas et al. J Antimicrob Chemother. .

Abstract

Background: The CDC reported a 35% increase in hospital-onset (HO) carbapenem-resistant Enterobacterales (CRE) infections during the COVID-19 pandemic. We evaluated patient outcomes following HO and community-onset (CO) CRE bloodstream infections (BSI).

Methods: Patients prospectively enrolled in CRACKLE-2 from 56 hospitals in 10 countries between 30 April 2016 and 30 November 2019 with a CRE BSI were eligible. Infections were defined as CO or HO by CDC guidelines, and clinical characteristics and outcomes were compared. The primary outcome was desirability of outcome ranking (DOOR) 30 days after index culture. Difference in 30-day mortality was calculated with 95% CI.

Results: Among 891 patients with CRE BSI, 65% were HO (582/891). Compared to those with CO CRE, patients with HO CRE were younger [median 60 (Q1 42, Q3 70) years versus 65 (52, 74); P < 0.001], had fewer comorbidities [median Charlson comorbidity index 2 (1, 4) versus 3 (1, 5); P = 0.002] and were more acutely ill (Pitt bacteraemia score ≥4: 47% versus 32%; P < 0.001). The probability of a better DOOR outcome in a randomly selected patient with CO BSI compared to a patient with HO BSI was 60.6% (95% CI: 56.8%-64.3%). Mortality at 30-days was 12% higher in HO BSI (192/582; 33%) than CO BSI [66/309 (21%); P < 0.001].

Conclusion: We found a disproportionately greater impact on patient outcomes with HO compared to CO CRE BSIs; thus, the recently reported increases in HO CRE infections by CDC requires rigorous surveillance and infection prevention methods to prevent added mortality.

Trial registration: ClinicalTrials.gov NCT03646227.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan–Meier curve of all-cause 30-day mortality by infection onset. Survival for 889 patients with CRE blood stream infection by infection onset type (CO versus hospital onset). Two subjects (one in each group) are excluded from the figure due to missing mortality outcome information. One subject in the HO group died on day 30 and is still considered at risk in the figure.

References

    1. Centers for Disease Control and Prevention . COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report, 2022. https://www.cdc.gov/drugresistance/covid19.html
    1. van Duin D, Arias CA, Komarow Let al. Molecular and clinical epidemiology of carbapenem-resistant enterobacterales in the USA (CRACKLE-2): a prospective cohort study. Lancet Infect Dis 2020; 20: 731–41. 10.1016/S1473-3099(19)30755-8 - DOI - PMC - PubMed
    1. Wang M, Earley M, Chen Let al. Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study. Lancet Infect Dis 2022; 22: 401–12. 10.1016/S1473-3099(21)00399-6 - DOI - PMC - PubMed
    1. Boutzoukas AE, Komarow L, Chen Let al. International epidemiology of carbapenemase-producing Escherichia coli. Clin Infect Dis 2023; 77: 499–509. 10.1093/cid/ciad288 - DOI - PMC - PubMed
    1. van Duin D, Lok JJ, Earley Met al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis 2018; 66: 163–71. 10.1093/cid/cix783 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

Associated data